0458GCC: A PHASE I DOSE ESCALATION STUDY OF INTRAVENOUS 17-AAG

0458GCC:静脉注射 17-AAG 的 I 期剂量递增研究

基本信息

  • 批准号:
    7608152
  • 负责人:
  • 金额:
    $ 4.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-03-01 至 2008-02-29
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Targeted cancer therapy has the potential benefit of affecting tumor cell pathways more specifically than normal tissues by utilizing agents with selectivity for those pathways activated in tumors. Since multiple growh regulatory pathways are altered in the common solid tumors, it follows that combinations of agents which can regulate common targets of those pathways, or agents that modulate distinct pathways, will likely comprise the combination chemotherapy regimens of the future. This protocol proposes to study one combination of such targeted therapies. 17-AAG is a benzoquinoid ansamycin antibiotic with antiproliferative activity for eucaryotic cells as well. Its parent compound, geldanamycin, showed promising anti-tumor activity in preclinical studies, but 17-AAG proved to be less hepatotoxic and more amenable to intravenous formulation. Both compounds act by binding to the ATP/ADP binding site on the heat shock protein 90 (Hsp90). Hsp90 is known to be critical for the normal folding and subsequnt localization to intracellular compartments and function of numerous regulators of cell proliferation including the Akt, Raf, erbB family, and CDK4 protein kinases, the hypoxia inducible factor (HIF1), and certain steroid hormone receptors including the androgen and estrogen receptors, among others. Inhibition of the the Hsp90 interaction with these Hsp90 "client" proteins results in their improper folding and subsequent degradation in the proteosome. The Raf family of kinases is particularly important in cellular proliferation. Rafs phosphorylate and activate Mek-1, which in turn phosphorylates and activates the exctracellular signal related kinases (Erks). Erk activation leads to activation and stimulation of a variety of anti-cell death and cell cycle activation pathways. Raf receives input from the erB2 family of tyrosine kinase and ras oncogene-related signaling pathways. Raf therefore sits at the center of numeropus regulatory pathways important in cellular proliferation. BAY 43-9006 (also known as sorafenib) is a small molecule that was specifically selected to have potent ability to interfere with Ras signaling. Subsequently, it was found to directly interact and inhibit the function of Raf, which is downstream of ras signaling. In addition, it has noteworthy activity against the Vascular Endothelial Growth Factoir (VEGF) receptor kinases, and therefore could portentially act to inhibit both proliferative and angiogenic pathways stimulating tumor growth. The combination of 17-AAG and BAY 43-9006 is particularly appealing to consider. 17-AAG is envisoned to able to down-regulate tyrosine kinase and raf by its Hsp-90 directed effects. BAY 43-9006 is envisioned to directly inhibit raf signaling. Therefore the combination of 17-AAG and BAY 43-9006 has the poitential to down-reguilate more efficiently proliferative signals acting through RAF and also affect VEGF -related pathways. The later result would be achieved gy 17-AAG modulation of HIF-1, and direct action of BAY-43-9006 on the VEGF-R. The trial proposed here would be a "first in humans" combination study of 17-AAG and BAY- 43-9006. We will score the adverse events, and define evidence of pharmacological interaction of the combination, as well as observe any evidence oif anti-tumor activity. In addition to these convential Phase I goals, we will define in all patients evidence of changes in the vascular permeability of the tumor by NMR techniques, as well as score effects of the combination on molecular targets of 17-AAG and /or BAY-43-9006 in peripheral blood mononuclear cells. Under a separate informed consent in patients with easily accessible tumor to needle biopsy, we will seek to define evidence of combined drug effect on relevant molecular markers in the tumoral compartment. Participation in tumor biopsies will not, however, be a requirement and patients can still participate in the protocol if they decline the biopsies.
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 靶向癌症治疗的潜在好处是,通过利用对肿瘤中激活的途径具有选择性的药物,比正常组织更具体地影响肿瘤细胞途径。由于多个Growh调节通路在常见实体肿瘤中发生改变,因此可以调节这些通路的共同靶点的药物组合,或调节不同途径的药物组合,很可能构成未来的联合化疗方案。该方案建议研究这种靶向疗法的一种组合。17-AAG是一种苯喹类阿萨霉素类抗生素,对真核细胞也具有抗增殖活性。它的母体化合物格尔达那霉素在临床前研究中显示出良好的抗肿瘤活性,但17-AAG被证明肝毒性较小,更容易静脉注射。这两种化合物都通过与热休克蛋白90(Hsp90)上的ATP/ADP结合位点结合来发挥作用。已知HSP90对多种细胞增殖调节因子的正常折叠和亚序列定位及其功能至关重要,其中包括Akt、Raf、erbB家族和CDK4蛋白激酶、低氧诱导因子(HIF1)以及某些类固醇激素受体,包括雄激素和雌激素受体等。抑制Hsp90与这些Hsp90“客户”蛋白的相互作用会导致它们不正确的折叠,从而导致蛋白质小体的降解。Raf蛋白家族在细胞增殖中起着特别重要的作用。RAF磷酸化并激活MEK-1,而MEK-1又磷酸化并激活细胞外信号相关激酶(ERK)。ERK的激活导致多种抗细胞死亡和细胞周期激活通路的激活和刺激。RAF从酪氨酸激酶和ras癌基因相关信号通路的ERB2家族接受输入。因此,RAF位于在细胞增殖中重要的Migopus调控通路的中心。Bay 43-9006(也称为sorafenib)是一种专门选择的小分子,具有强大的干扰RAS信号的能力。随后,人们发现它直接相互作用并抑制ras信号下游的Raf的功能。此外,它还具有显著的抗血管内皮细胞生长因子(VEGF)受体激酶的活性,因此可以抑制刺激肿瘤生长的增殖和血管生成途径。17-AAG和Bay 43-9006的组合特别值得考虑。17-AAG被认为能够通过其HSP-90的定向作用下调酪氨酸激酶和RAF。BAY 43-9006被设想为直接抑制RAF信号。因此,17-AAG和Bay 43-9006联合使用可能下调通过RAF作用的更有效的增殖信号,并影响血管内皮生长因子相关通路。后者可能通过17-AAG对HIF-1的调控和Bay-43-9006对血管内皮细胞生长因子受体的直接作用来实现。这里提出的试验将是17-AAG和Bay-43-9006的“首次人类”联合研究。我们将对不良事件进行评分,确定联合用药的药理相互作用的证据,并观察任何抗肿瘤活性的证据。除了这些常规的第一阶段目标外,我们还将通过核磁共振技术在所有患者中确定肿瘤血管渗透性变化的证据,以及联合使用对外周血单核细胞中17-AAG和/或Bay-43-9006分子靶标的评分影响。根据单独的知情同意,对于容易接受针吸活检的肿瘤患者,我们将寻求确定联合药物对肿瘤间隔区相关分子标志物影响的证据。然而,参与肿瘤活组织检查不是必须的,如果患者拒绝活组织检查,他们仍然可以参与该方案。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD A. SAUSVILLE其他文献

EDWARD A. SAUSVILLE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD A. SAUSVILLE', 18)}}的其他基金

CLINICAL TRIAL: TREATMENT OF MELANOMA WITH WILD-TYPE P53 AND A 100B USING PENTA
临床试验:使用 PENTA 使用野生型 P53 和 A 100B 治疗黑色素瘤
  • 批准号:
    7951182
  • 财政年份:
    2009
  • 资助金额:
    $ 4.07万
  • 项目类别:
UMGCC Paul Calabresi Clinical Oncology Training Program
UMGCC Paul Calabresi 临床肿瘤学培训计划
  • 批准号:
    8332885
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:
UMGCC Paul Calabresi Clinical Oncology Training Program
UMGCC Paul Calabresi 临床肿瘤学培训计划
  • 批准号:
    7928077
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:
UMGCC Paul Calabresi Clinical Oncology Training Program
UMGCC Paul Calabresi 临床肿瘤学培训计划
  • 批准号:
    7470184
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:
Treatment of Melanoma with wild-type P53 and detectable S100B using pentamidine:
使用喷他脒用野生型 P53 和可检测的 S100B 治疗黑色素瘤:
  • 批准号:
    7529101
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:
Clinical Research Shared Service
临床研究共享服务
  • 批准号:
    7696610
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:
UMGCC Paul Calabresi Clinical Oncology Training Program
UMGCC Paul Calabresi 临床肿瘤学培训计划
  • 批准号:
    8141280
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:
Treatment of Melanoma with wild-type P53 and detectable S100B using pentamidine:
使用喷他脒用野生型 P53 和可检测的 S100B 治疗黑色素瘤:
  • 批准号:
    7642487
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:
UMGCC Paul Calabresi Clinical Oncology Training Program
UMGCC Paul Calabresi 临床肿瘤学培训计划
  • 批准号:
    8548092
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:
UMGCC Paul Calabresi Clinical Oncology Training Program
UMGCC Paul Calabresi 临床肿瘤学培训计划
  • 批准号:
    7683191
  • 财政年份:
    2008
  • 资助金额:
    $ 4.07万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 4.07万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 4.07万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 4.07万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 4.07万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 4.07万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 4.07万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 4.07万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 4.07万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 4.07万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 4.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了